6.
Lurain K
. Treating Cancer in People With HIV. J Clin Oncol. 2023; 41(21):3682-3688.
PMC: 10351946.
DOI: 10.1200/JCO.23.00737.
View
7.
Lenz G, Wright G, Emre N, Kohlhammer H, Dave S, Davis R
. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008; 105(36):13520-5.
PMC: 2533222.
DOI: 10.1073/pnas.0804295105.
View
8.
Sullivan P, Satcher Johnson A, Pembleton E, Stephenson R, Justice A, Althoff K
. Epidemiology of HIV in the USA: epidemic burden, inequities, contexts, and responses. Lancet. 2021; 397(10279):1095-1106.
DOI: 10.1016/S0140-6736(21)00395-0.
View
9.
Wright G, Tan B, Rosenwald A, Hurt E, Wiestner A, Staudt L
. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003; 100(17):9991-6.
PMC: 187912.
DOI: 10.1073/pnas.1732008100.
View
10.
Keane C, Gould C, Jones K, Hamm D, Talaulikar D, Ellis J
. The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma. Clin Cancer Res. 2016; 23(7):1820-1828.
DOI: 10.1158/1078-0432.CCR-16-1576.
View
11.
Baum P, Young J, Schmidt D, Zhang Q, Hoh R, Busch M
. Blood T-cell receptor diversity decreases during the course of HIV infection, but the potential for a diverse repertoire persists. Blood. 2012; 119(15):3469-77.
PMC: 3325037.
DOI: 10.1182/blood-2011-11-395384.
View
12.
Frontzek F, Staiger A, Wullenkord R, Grau M, Zapukhlyak M, Kurz K
. Molecular profiling of EBV associated diffuse large B-cell lymphoma. Leukemia. 2023; 37(3):670-679.
PMC: 9991915.
DOI: 10.1038/s41375-022-01804-w.
View
13.
Masenga S, Mweene B, Luwaya E, Muchaili L, Chona M, Kirabo A
. HIV-Host Cell Interactions. Cells. 2023; 12(10.
PMC: 10216808.
DOI: 10.3390/cells12101351.
View
14.
Jelicic J, Juul-Jensen K, Bukumiric Z, Clausen M, Al-Mashhadi A, Schou Pedersen R
. Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models. Blood Cancer J. 2023; 13(1):157.
PMC: 10575851.
DOI: 10.1038/s41408-023-00930-7.
View
15.
Warren J, Clutton G, Goonetilleke N
. Harnessing CD8 T Cells Under HIV Antiretroviral Therapy. Front Immunol. 2019; 10:291.
PMC: 6400228.
DOI: 10.3389/fimmu.2019.00291.
View
16.
Mastrangelo A, Banga R, Perreau M
. Elite and posttreatment controllers, two facets of HIV control. Curr Opin HIV AIDS. 2022; 17(5):325-332.
PMC: 10004771.
DOI: 10.1097/COH.0000000000000751.
View
17.
Hans C, Weisenburger D, Greiner T, Gascoyne R, Delabie J, Ott G
. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2003; 103(1):275-82.
DOI: 10.1182/blood-2003-05-1545.
View
18.
Lunardi L, Bragatte M, Vieira G
. The influence of HLA/HIV genetics on the occurrence of elite controllers and a need for therapeutics geotargeting view. Braz J Infect Dis. 2021; 25(5):101619.
PMC: 9392165.
DOI: 10.1016/j.bjid.2021.101619.
View
19.
Porciello N, Franzese O, DAmbrosio L, Palermo B, Nistico P
. T-cell repertoire diversity: friend or foe for protective antitumor response?. J Exp Clin Cancer Res. 2022; 41(1):356.
PMC: 9773533.
DOI: 10.1186/s13046-022-02566-0.
View
20.
Cesarman E
. Pathology of lymphoma in HIV. Curr Opin Oncol. 2013; 25(5):487-94.
PMC: 4126602.
DOI: 10.1097/01.cco.0000432525.70099.a4.
View